120 related articles for article (PubMed ID: 38691509)
1. Stocking and supplying naloxone: Findings from a representative sample of community pharmacies in Victoria, Australia.
Karthikeyan N; Xia T; Nielsen S; Picco L
Drug Alcohol Rev; 2024 May; ():. PubMed ID: 38691509
[TBL] [Abstract][Full Text] [Related]
2. Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016.
Meyerson BE; Agley JD; Davis A; Jayawardene W; Hoss A; Shannon DJ; Ryder PT; Ritchie K; Gassman R
Drug Alcohol Depend; 2018 Jul; 188():187-192. PubMed ID: 29778772
[TBL] [Abstract][Full Text] [Related]
3. Community pharmacist knowledge, attitudes and confidence regarding naloxone for overdose reversal.
Nielsen S; Menon N; Larney S; Farrell M; Degenhardt L
Addiction; 2016 Dec; 111(12):2177-2186. PubMed ID: 27367125
[TBL] [Abstract][Full Text] [Related]
4. Attitudes and availability: A comparison of naloxone dispensing across chain and independent pharmacies in rural and urban areas in Alabama.
Sisson ML; McMahan KB; Chichester KR; Galbraith JW; Cropsey KL
Int J Drug Policy; 2019 Dec; 74():229-235. PubMed ID: 31698165
[TBL] [Abstract][Full Text] [Related]
5. Socio-ecological and pharmacy-level factors associated with buprenorphine stocking at pharmacies in New York City.
Marotta PL; Abbas BT; Stringer K; Huang D; Schnaidt J; Goddard-Eckrich D; El-Bassel N; Gilbert L
Int J Drug Policy; 2021 Nov; 97():103321. PubMed ID: 34358803
[TBL] [Abstract][Full Text] [Related]
6. Pharmacist furnishing of naloxone in California: A follow-up analysis.
Puzantian T; Gasper JJ; Ramirez CM
J Am Pharm Assoc (2003); 2021; 61(5):e108-e112. PubMed ID: 34246575
[TBL] [Abstract][Full Text] [Related]
7. What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy.
Nielsen S; Sanfilippo P; Picco L; Bruno R; Kowalski M; Wood P; Larney S
Int J Clin Pharm; 2021 Apr; 43(2):420-429. PubMed ID: 32533428
[TBL] [Abstract][Full Text] [Related]
8. Assessment of naloxone availability in Georgia community pharmacies.
Stone RH; Hur S; Young HN
J Am Pharm Assoc (2003); 2020; 60(2):357-361. PubMed ID: 31866387
[TBL] [Abstract][Full Text] [Related]
9. Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study.
Nielsen S; Picco L; Kowalski M; Sanfilippo P; Wood P; Larney S; Bruno R; Ritter A
Res Social Adm Pharm; 2020 Dec; 16(12):1694-1701. PubMed ID: 32273255
[TBL] [Abstract][Full Text] [Related]
10. Naloxone accessibility without an outside prescription from U.S. community pharmacies: A systematic review.
Lai RK; Friedson KE; Reveles KR; Bhakta K; Gonzales G; Hill LG; Evoy KE
J Am Pharm Assoc (2003); 2022; 62(6):1725-1740. PubMed ID: 35989151
[TBL] [Abstract][Full Text] [Related]
11. Pharmacy on-site overdose protocols and prevention of overdose.
Green TC; Soipe A; Baloy B; Burstein D; Xuan Z; Tapper A; Walley AY; Case P; Bratberg J; Baird J
Subst Abus; 2022; 43(1):64-68. PubMed ID: 32186478
[TBL] [Abstract][Full Text] [Related]
12. Factors associated with prescription drug monitoring program utilisation: a cross-sectional survey of community pharmacists.
Picco L; Lam T; Xia T; Nielsen S
Int J Clin Pharm; 2023 Apr; 45(2):421-429. PubMed ID: 36528707
[TBL] [Abstract][Full Text] [Related]
13. Using the behaviour change wheel to understand and address barriers to pharmacy naloxone supply in Australia.
Nielsen S; Olsen A
Int J Drug Policy; 2021 Apr; 90():103061. PubMed ID: 33321285
[TBL] [Abstract][Full Text] [Related]
14. Naloxone availability and dispensing in Indiana pharmacies 2 years after the implementation of a statewide standing order.
Eldridge LA; Agley J; Meyerson BE
J Am Pharm Assoc (2003); 2020; 60(3):470-474. PubMed ID: 31917248
[TBL] [Abstract][Full Text] [Related]
15. Pharmacists' readiness to provide naloxone in community pharmacies in West Virginia.
Thornton JD; Lyvers E; Scott VGG; Dwibedi N
J Am Pharm Assoc (2003); 2017; 57(2S):S12-S18.e4. PubMed ID: 28163027
[TBL] [Abstract][Full Text] [Related]
16. Pharmacy naloxone codispensing: A mixed methods study of practices and perspectives under a statewide standing order program.
Pollini RA; Slocum S; Ozga JE; Joyce R; Xuan Z; Green TC; Walley AY
J Am Pharm Assoc (2003); 2022; 62(5):1546-1554. PubMed ID: 35450833
[TBL] [Abstract][Full Text] [Related]
17. Buprenorphine and naloxone access in pharmacies within high overdose areas of Los Angeles during the COVID-19 pandemic.
Dadiomov D; Bolshakova M; Mikhaeilyan M; Trotzky-Sirr R
Harm Reduct J; 2022 Jun; 19(1):69. PubMed ID: 35768817
[TBL] [Abstract][Full Text] [Related]
18. Demographic and socioeconomic correlates to buprenorphine access in pharmacies.
Welsh JW; Yarbrough CR; Sitar SI; Mataczynski MJ; Peralta AM; Kan M; Crawford ND; Conrad TA; Kee C; Young HN
J Am Pharm Assoc (2003); 2023; 63(3):751-759. PubMed ID: 36658013
[TBL] [Abstract][Full Text] [Related]
19. Preparing pharmacists to increase naloxone dispensing within community pharmacies under the Pennsylvania standing order.
Santa HM; Amirova SG; Ventricelli DJ; Downs GE; Nowalk AA; Pringle JL; Aruru M
Am J Health Syst Pharm; 2021 Feb; 78(4):327-335. PubMed ID: 33336254
[TBL] [Abstract][Full Text] [Related]
20. Naloxone availability in independent community pharmacies in Georgia, 2019.
Gilbert L; Elliott J; Beasley L; Oranu E; Roth K; Nguyễn J
Subst Abuse Treat Prev Policy; 2021 Aug; 16(1):63. PubMed ID: 34419089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
